- Home
- CHRS vs PLCE Comparison
CHRS vs PLCE Comparison
Compare CHRS & PLCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- PLCE
- Stock Information
- Founded
- CHRS 2010
- PLCE 1969
- Country
- CHRS United States
- PLCE United States
- Employees
- CHRS N/A
- PLCE N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- PLCE Clothing/Shoe/Accessory Stores
- Sector
- CHRS Health Care
- PLCE Consumer Discretionary
- Exchange
- CHRS Nasdaq
- PLCE Nasdaq
- Market Cap
- CHRS 194.1M
- PLCE 169.6M
- IPO Year
- CHRS 2014
- PLCE 1997
- Fundamental
- Price
- CHRS $1.70
- PLCE $7.70
- Analyst Decision
- CHRS Strong Buy
- PLCE Hold
- Analyst Count
- CHRS 4
- PLCE 1
- Target Price
- CHRS $4.51
- PLCE $7.00
- AVG Volume (30 Days)
- CHRS 1.0M
- PLCE 551.9K
- Earning Date
- CHRS 11-07-2025
- PLCE 12-02-2025
- Dividend Yield
- CHRS N/A
- PLCE N/A
- EPS Growth
- CHRS N/A
- PLCE N/A
- EPS
- CHRS 1.55
- PLCE N/A
- Revenue
- CHRS $272,209,000.00
- PLCE $1,338,867,000.00
- Revenue This Year
- CHRS N/A
- PLCE N/A
- Revenue Next Year
- CHRS $109.48
- PLCE $0.68
- P/E Ratio
- CHRS $3.38
- PLCE N/A
- Revenue Growth
- CHRS 52.33
- PLCE N/A
- 52 Week Low
- CHRS $0.66
- PLCE $3.66
- 52 Week High
- CHRS $2.43
- PLCE $17.19
- Technical
- Relative Strength Index (RSI)
- CHRS 54.43
- PLCE 52.35
- Support Level
- CHRS $1.64
- PLCE $7.10
- Resistance Level
- CHRS $1.81
- PLCE $8.87
- Average True Range (ATR)
- CHRS 0.10
- PLCE 0.70
- MACD
- CHRS -0.02
- PLCE -0.06
- Stochastic Oscillator
- CHRS 42.32
- PLCE 32.97
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.